Lidothol Es System
Product Images NDC 87063-323

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Lidothol Es (NDC 87063-323). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Asclemed Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lidocaine (Asset 1)

Chemical structure diagram of the active ingredient lidocaine, showing its aromatic ring with two methyl groups, an amide linkage, and a diethylaminoethyl side chain.*

FDA Label Image

Menthol (Asset 2)

Chemical structure of menthol, showing a cyclohexane ring with hydroxyl and methyl groups attached.*

FDA Label Image

Figure1 (Asset 3)

A line graph showing plasma lidocaine concentration (ng/mL) versus time (hours) over a 72-hour period. Data points exhibit a repeating cyclical pattern with peaks approximately every 24 hours, indicating fluctuating plasma levels of lidocaine after administration.*

FDA Label Image

Figure2 (Asset 4)

Chemical structure diagram illustrating the proposed metabolic pathway of menthol. It shows menthol converting into various hydroxylated and carboxylated metabolites, including para-Menthane-3,7-diol, para-Menthane-3,9-diol, para-Menthane-3,8-diol, Menthol-9-carboxylic acid, and 3,8-Dihydro-para-menthane-7-carboxylic acid, as well as the formation of an O-glucuronide conjugate involved in enterophepatic circulation and elimination via urine and feces.*

FDA Label Image

Di Table (Di Table)

A table listing drug classes and examples of drugs within each class. It includes categories such as nitrates/nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs, with specific examples like nitroglycerin, lidocaine, cyclophosphamide, dapsone, chloroquine, phenytoin, and acetaminophen.*

FDA Label Image

1 (Label)

The label for Lidothol ES transdermal system containing menthol 5% and lidocaine 4%, manufactured for Clinic Pharma by Enovachem Pharmaceuticals. The label shows the NDC 87063-323-15, package quantity of 15 units, and a description noting 15 patches with menthol 5% drug-in-adhesive system. Storage instructions advise keeping the product at 20-25°C (68-77°F) and to keep out of reach of children. The drug is prescription only (RX).*

FDA Label Image

Table1 (Table1)

Table presenting absorption data for Lidocaine 5% Patch applied on the back of normal volunteers, worn for 12 hours. Data includes application site, area in cm², dose absorbed in mg, maximum concentration (Cmax) in µg/mL, and time to maximum concentration (Tmax) in hours for 3 patches totaling 2100 mg.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.